| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| UNITED STATES | Region | 2025 | USD | 37,078.0 | 59.3% |
| Developed Rest Of World | Region | 2025 | USD | 16,188.0 | 25.9% |
| Emerging Markets | Region | 2025 | USD | 9,313.0 | 14.9% |
| UNITED STATES | Region | 2024 | USD | 38,691.0 | 60.8% |
| Developed Rest Of World | Region | 2024 | USD | 16,057.0 | 25.2% |
| Emerging Markets | Region | 2024 | USD | 8,879.0 | 14.0% |
| UNITED STATES | Region | 2023 | USD | 27,088.0 | 46.3% |
| Emerging Markets | Region | 2023 | USD | 11,996.0 | 20.5% |
| Developed Europe | Region | 2023 | USD | 11,650.0 | 19.9% |
| Developed Rest Of World | Region | 2023 | USD | 7,761.0 | 13.3% |
| UNITED STATES | Region | 2022 | USD | 42,473.0 | 42.3% |
| Developed Europe | Region | 2022 | USD | 21,982.0 | 21.9% |
| Emerging Markets | Region | 2022 | USD | 20,097.0 | 20.0% |
| Developed Rest Of World | Region | 2022 | USD | 15,778.0 | 15.7% |
| UNITED STATES | Region | 2021 | USD | 29,746.0 | 36.6% |
| Emerging Markets | Region | 2021 | USD | 20,701.0 | 25.5% |
| Developed Europe | Region | 2021 | USD | 18,336.0 | 22.6% |
| Developed Rest Of World | Region | 2021 | USD | 12,506.0 | 15.4% |
| UNITED STATES | Region | 2020 | USD | 21,712.0 | 51.8% |
| Emerging Markets | Region | 2020 | USD | 8,372.0 | 20.0% |
| Developed Europe | Region | 2020 | USD | 7,788.0 | 18.6% |
| Developed Rest Of World | Region | 2020 | USD | 4,036.0 | 9.6% |
| Biopharma Segment | Product | 2025 | USD | 61,199.0 | 97.8% |
| Segment Reporting, Reconciling Item, Corporate Nonsegment | Product | 2025 | USD | 1,380.0 | 2.2% |
| Biopharma Segment | Product | 2024 | USD | 62,400.0 | 100.0% |
| Biopharma Segment | Product | 2023 | USD | 57,186.0 | 97.8% |
| Business Innovation Segment | Product | 2023 | USD | 1,310.0 | 2.2% |
| Biopharma Segment | Product | 2022 | USD | 98,988.0 | 100.0% |
| Biopharma Segment | Product | 2021 | USD | 79,557.0 | 100.0% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
